Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about LNTH, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Perflutren FDA approved Jul 2001 · Definity |
Coronary Artery Disease | Phase 4 · NCT00162370 | Completed |
| Florbetaben (18F) FDA approved Mar 2014 · Neuraceq |
Cardiac Amyloidosis | Phase 3 · NCT05184088 | Completed |
| Florbetaben F 18 | Alzheimer's Disease (AD) | Phase 4 · NCT02681172 | Completed |
| Fluorine F 18 Flurpiridaz | Coronary Artery Disease | Phase 3 · NCT01347710 | Completed |
| [18F]PI-2620 | Alzheimer Disease | Phase 3 · NCT05641688 | Recruiting |
| [68Ga]-LNTH-2401 | Prostate Cancer | Phase 2/3 · NCT07831824 | Recruiting |
| 99mTechnicium (sestamibi or tetrofosmin) | Coronary Artery Disease | Phase 3 · NCT01347710 | Completed |
| Lutetium Lu 177-DOTA-DUNP19 LNTH2403 | Relapsed / Refractory Osteosarcoma | Phase 1/2 · NCT07357519 | Recruiting |
| Sulfur hexafluoride lipid microspheres | Von-Hippel Lindau | Phase 2 · NCT03907657 | Completed |
| Phase 2; LNTH2403 a single agent recommended… | Relapsed / Refractory Osteosarcoma | Phase 1/2 · NCT07357519 | Recruiting |
| Lutetium Lu 177 Zadavotide Guraxetan | Metastatic Renal Cell Carcinoma | Phase 1/2 · NCT06361810 | Withdrawn |
| Androgen Receptor Pathway Inhibitor | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 2 · NCT07645326 | Not yet recruiting |
| Fluorine F 18 Piflufolastat | Prostate Cancer Diagnosis | Phase 2 · NCT05820724 | Unknown |
| Androgen Deprivation Therapy (ADT) | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 2 · NCT07645326 | Not yet recruiting |
| LMI 1195-101 | Heart Failure | Phase 1 · NCT00891241 | Completed |
| Fludeoxyglucose (18F)-IBA | Diagnostic Imaging | Phase 1 · NCT01089998 | Completed |
Also used in these trials (approved or third-party drugs, not LNTH's own candidates): Piflufolastat F-18, Pembrolizumab, Docetaxel Anhydrous.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
LNTH holds $683.6M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LNTH files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Lantheus Omega, LLC | 5%+ holder (13G) | 792,958,513 | 1,212.45% | 2026-07-28 |
| Lantheus Holdings, Inc. 10% owner |
Insider | 11,563,425 | 17.68% | 2026-09-01 |
| Lantheus Alpha Therapy, LLC 10% owner |
Insider | 11,273,364 | 17.24% | 2026-09-03 |
| Dapice Joshua J. | 5%+ holder (13G) | 5,427,479 | 8.30% | 2025-12-31 |
| Pentwater Capital Management LP | Institution (13G, 5%+) | 3,900,000 | 5.96% | 2026-09-30 |
| FARALLON PARTNERS L L C/CA 10% owner |
Insider | 3,477,227 | 5.32% | 2025-08-19 |
| Rajiv A Patel Member of a Group Owning 10% Includes shares also reported by FARALLON PARTNERS L L C/CA, counted once |
Insider | 3,477,227 | 5.32% | 2025-08-19 |
| Vanguard Capital Management | Institution (13G, 5%+) | 3,421,414 | 5.23% | 2026-03-31 |
| Mary Anne Heino Executive Chair and CEO, Director · +26,325 options |
Insider | 587,968 | 0.90% | 2026-05-14 |
| Robert J. Jr. Marshall CFO and Treasurer |
Insider | 122,071 | 0.19% | 2026-08-31 |
| Daniel Niedzwiecki Chief Administrative Officer, General Co |
Insider | 117,465 | 0.18% | 2026-04-17 |
| Paul Blanchfield President |
Insider | 108,214 | 0.17% | 2025-08-13 |
Share count 65,401,413 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-03-06 | PYLARIFY TruVu | NDA | +15.6% | -4.9% | +5.4% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LNTH and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →